RxDoctor Payments Data

Michelle Horev

Physician Assistant · Miami, FLNPI 1831868421

Payments from drug & device makers

$4,618in general payments, 2019–2025

Across 173 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$853
  • Actelion Pharmaceuticals US, Inc.$581
  • Merck$567
  • Bayer$349
  • Alnylam Pharmaceuticals Inc.$332
  • Impulse Dynamics (USA) Inc.$325
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,40995%
  • Education$2085%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,618 in reported general payments places this provider in the 85th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$45,195
Medicare patients
114
Services billed
624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan235$264,883
EliquisApixaban185$190,683
FarxigaDapagliflozin Propanediol167$175,602
JardianceEmpagliflozin75$73,577
XareltoRivaroxaban39$43,201
VeltassaPatiromer Calcium Sorbitex22$21,312
OzempicSemaglutide12$11,289
LokelmaSodium Zirconium Cyclosilicate11$9,702
Bumetanide253$4,871
Metoprolol Succinate268$3,452
Atorvastatin Calcium199$2,449
Spironolactone293$2,010
Bisoprolol Fumarate72$1,474
Rosuvastatin Calcium82$1,256
Eplerenone16$1,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$74$264,883235 claims
PfizerEliquis$292$190,683185 claims
AstraZenecaFarxiga, Lokelma$853$185,304178 claims
Johnson & JohnsonXarelto$137$43,20139 claims
Novo NordiskOzempic$304$11,28912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →